Skip to content

US · INM · BIOTECHNOLOGY

InMed Pharmaceuticals Inc. (INM) intrinsic value and stock valuation

$15.56as of 2026-11-21 · Mkt cap 2.53M

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

InMed Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values INM with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from INM’s statements →

InMed Pharmaceuticals Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Vancouver, BC V6C 3E8 inmedpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$4.94M
20112025
Net income
-$-8.16M
20112025
Free cash flow
-$-7.77M
20112025
Total equity
$18.3M+25.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$4.94M$4.6M$4.14M$1.09M$0.00
Operating income-$-7.92M-$-8.13M-$-8.38M-$-13.79M-$-12.17M
Net income-$-8.16M-$-7.68M-$-7.95M-$-18.6M-$-12.65M
EPSd-$-8.33M-$-20.21M-$-66.25M—-$-1.27B
Operating cash flow-$-7.77M-$-6.99M-$-7.28M-$-15.58M-$-9.79M
Capital expenditure$0.00-$-10K-$-160K-$-40K-$0.00
Free cash flow-$-7.77M-$-7M-$-7.45M-$-15.62M-$-9.79M
Total assets$21.2M$16.2M$18.7M$16.5M$12.1M
Total debt$1.01M$1.32M$520K$1.02M$330K
Net debt-$-14.08M-$-7.67M-$-11.29M-$-6.93M-$-8.77M
Total equity$18.3M$12.6M$16M$11.7M$9.12M
Cash and short-term investments$15.1M$8.99M$11.8M$8.01M$9.16M
Income statement
20252024202320222021
Revenue$4.94M$4.6M$4.14M$1.09M$0.00
Cost of revenue$3.24M$3.5M$2.73M$550K$0.00
Gross profit$1.71M$1.1M$1.4M$540K$0.00
Research and development expenses$2.85M$3.22M$3.73M$7.28M$6.62M
Selling, general and administrative expenses$6.56M$5.8M$5.85M$6.87M$5.55M
Other expenses$210K$220K$200K$190K$0.00
Operating expenses$9.62M$9.24M$9.78M$14.3M$12.2M
Cost and expenses$12.9M$12.7M$12.5M$14.9M$12.2M
Interest income$160K$720K$650K$120K$20K
Interest expense$370K$0.00$0.00$0.00$360K
Depreciation and amortization$530K$600K$600K$510K$150K
Ebitda-$-7.26M-$-7.06M-$-7.34M-$-18.09M-$-12.17M
Operating income-$-7.92M-$-8.13M-$-8.38M-$-13.79M-$-12.17M
Total other income/expenses, net-$-240K$470K$440K-$-4.81M-$-480K
Income before tax-$-8.16M-$-7.67M-$-7.93M-$-18.6M-$-12.65M
Income tax expense$0.00$10K$10K$0.00$0.00
Net income-$-8.16M-$-7.68M-$-7.95M-$-18.6M-$-12.65M
Weighted average shares outstanding$980K$380K$120K$0.00$10K
Weighted average diluted shares outstanding$980K$380K$120K$0.00$10K
Balance sheet
20252024202320222021
Cash and short-term investments$15.1M$8.99M$11.8M$8.01M$9.16M
Net receivables$630K$480K$340K$110K$10K
Inventory$1.31M$1.7M$2.14M$3.21M$0.00
Total current assets$17.5M$11.9M$15M$12.4M$10.4M
Property, plant and equipment, net$1.35M$1.71M$960K$1.16M$400K
Goodwill and intangible assets$2.21M$2.44M$2.58M$2.72M$1.31M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.7M$4.29M$3.68M$4.11M$1.74M
Total assets$21.2M$16.2M$18.7M$16.5M$12.1M
Accounts payable$500K$860K$720K$1.5M$960K
Short-term debt$590K$430K$500K$520K$100K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.51M$2.7M$2.65M$4.27M$2.74M
Long-term debt$420K$880K$20K$500K$230K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$420K$880K$20K$500K$230K
Capital lease obligations$1.01M$1.32M$520K$1.02M$330K
Total liabilities$2.92M$3.58M$2.67M$4.78M$2.97M
Common stock$124.3M$113.2M$102.8M$91.1M$74.9M
Retained earnings-$-159.73M-$-149.18M-$-134.33M-$-120.33M-$-92.57M
Accumulated other comprehensive income (loss)$180K$180K$170K$170K$160K
Total equity$18.3M$12.6M$16M$11.7M$9.12M
Total investments$0.00$0.00$0.00$60K$60K
Total debt$1.01M$1.32M$520K$1.02M$330K
Net debt-$-14.08M-$-7.67M-$-11.29M-$-6.93M-$-8.77M
Cash flow statement
20252024202320222021
Net income-$-8.16M-$-7.68M-$-7.95M-$-18.6M-$-10.2M
Depreciation and amortization$530K$600K$600K$510K$120K
Stock-based compensation$120K$140K$280K$700K$610K
Change in working capital-$-340K-$-370K-$-570K-$-3.07M-$-450K
Accounts receivable-$-110K-$-90K-$-220K-$-40K$40K
Inventory$280K$70K$570K-$-2M$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-7.77M-$-6.99M-$-7.28M-$-15.58M-$-9.79M
Investments in property, plant and equipment$0.00-$-10K-$-160K-$-40K-$0.00
Acquisitions, net$0.00$0.00-$-500K-$-210K$0.00
Net cash used for investing activities$0.00-$-10K-$-660K-$-670K-$0.00
Common stock issued$8.13M$5.22M$10.7M$17.2M$12.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.3M$4.65M$10.7M$15.1M$10.9M
Net change in cash$4.5M-$-2.34M$2.74M-$-1.19M$1.56M
Cash at end of period$11.1M$6.57M$8.91M$6.18M$7.36M
Operating cash flow-$-7.77M-$-6.99M-$-7.28M-$-15.58M-$-9.79M
Capital expenditure$0.00-$-10K-$-160K-$-40K-$0.00
Free cash flow-$-7.77M-$-7M-$-7.45M-$-15.62M-$-9.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About InMed Pharmaceuticals Inc.

        InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.

        CEO
        Eric A. Adams Chem.
        Employees
        13
        Beta
        0.95

        Explore

        Frequently asked questions

        What is the intrinsic value of InMed Pharmaceuticals Inc. (INM)?

        InMed Pharmaceuticals Inc. (INM) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is INM undervalued?

        INM trades at a price of $15.56 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.